Direct comparison of iPSC-CPCs and endogenous CPCs
Research type
Research Study
Full title
Therapeutic potential of human induced pluripotent stem cell-derived cardiac progenitor cells: Direct comparison with endogenous cardiac progenitor cells from the same patients
IRAS ID
280250
Contact name
Fiona Lewis-McDougall
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Myocardial infarction and subsequent heart failure are the cause of more deaths, morbidity, and financial burden than any other group of diseases. Endogenous c-kit+ cardiac progenitor cells (eCPCs) have been shown to significantly alleviate cardiac damage in both acute and chronic settings however eCPCs are also susceptible to aging-related deterioration and their isolation requires an invasive cardiac biopsy. We hypothesise that a novel, expandable CPC population can be generated through generation of induced pluripotent stem cells (iPSCs) from patient skin cells followed by early selection of c-kit+ iPSC-CPCs. This offers unique advantages both as a research tool and a therapeutic cell source. To achieve this, we will directly compare human c-kit+ eCPCs and iPSC-CPCs from the same donors, which will define the optimal cell type to improve clinical outcome.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
20/LO/0869
Date of REC Opinion
31 Jul 2020
REC opinion
Further Information Favourable Opinion